Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2012

View Archived Issues

New GlyT1 inhibitors patented

Nuvilex provides information on cell encapsulation technology

New nanovector platform allows noncovalent assembly of targeted therapeutics

Promedior closes financing round to advance pipeline

Dr. Falk Pharma obtains European rights to ulcerative colitis drug candidate

Dendritic cell-based vaccine is safe in patients with HIV

Novartis transfers marketing rights for ophthalmic solution

Taiho Pharmaceutical terminates licensing agreement for antipruritic agent

Aegerion Pharmaceuticals provides update on lomitapide NDA

Moberg Derma receives clearance for phase I Limtop trial

New phosphodiesterase 10A inhibitors reported by Evotec

Shionogi & Co. presents novel P2X3 and P2X2/3 receptor antagonists

Avedro submits NDA for corneal cross-linking system

S&T Global designs novel candidate antivirals

New PARP-1 inhibitors with anticancer potential developed in China

Roche divulges new seprase-specific antibodies

Research at Glycotope results in new potential cancer immunotherapies

Novel candidate schizophrenia therapeutics identified

Novel RIPK2 inhibitors reported by GlaxoSmithKline

Roche describes novel potential cancer therapeutics

Janssen unblinds phase III Zytiga study

Teva and OncoGenex amend custirsen advanced prostate cancer program

BioMarin completes enrollment in phase III BMN-110 trial

Transparency Life Sciences in-licenses ACE inhibitor

Novo Nordisk seeks Japanese approval for insulin degludec/insulin aspart coformulation

Peregrine reports topline clinical data on bavituximab

Inviragen reports topline results from HFMD vaccine study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...